Results 21 to 30 of about 72,428 (200)
Human and Experimental Toxicology, 2023 Ferroptosis is potential to relieve drug resistance in hepatocellular carcinoma (HCC). Glutathione peroxidase 4 (GPX4) is a critical modulator of ferroptosis. This study discussed the mechanism of GPX4-inhibited ferroptosis in sorafenib resistance in HCC.
Xiaoming Li +4 more
semanticscholar +1 more source
Cell Proliferation, 2021 Evidences demonstrate that sorafenib alleviates liver fibrosis via inhibiting HSC activation and ECM accumulation. The underlying mechanism remains unclear.
Siyu Yuan +7 more
semanticscholar +1 more source
Non-Coding RNA, 2022 The multikinase inhibitor, sorafenib, is a first-line treatment for hepatocellular carcinoma (HCC), but its limited efficacy, drug resistance and toxicity are a concern.
Qingchun Lu +5 more
doaj +1 more source
Hepatology, EarlyView., 2022 Steatotic HCC can be diagnosed by MRI and forms a pro‐tumor immune microenvironment with high expression of PD‐L1, M2 polarization of macrophages and activation of CAFs, which may be a good target for combined immunotherapy. Abstract Background and Aims Immunotherapy has become the standard‐of‐care treatment for hepatocellular carcinoma (HCC), but its ...
Hiroki Murai +29 more
wiley +1 more source
Cellular and Molecular Gastroenterology and Hepatology, 2020 Background & Aims: Sorafenib is a multireceptor tyrosine kinase inhibitor that can prolong overall survival in patients with advanced hepatocellular carcinoma (HCC). Although most HCC patients who receive sorafenib ultimately show disease progression,
Tomomi Hashiba +19 more
doaj +1 more source
Journal of experimental & clinical cancer research : CR, 2022 Background Drug resistance to sorafenib greatly limited the benefits of treatment in patients with hepatocellular carcinoma (HCC). MicroRNAs (miRNAs) participate in the development of drug resistance.
Yuanjun Lu +10 more
semanticscholar +1 more source
Proteogenomic characterization of cholangiocarcinoma
Hepatology, EarlyView., 2022 Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng +18 more
wiley +1 more source
Neoplasia: An International Journal for Oncology Research, 2014 Hepatocellular carcinoma is the fifth most common solid cancer worldwide. Sorafenib, a small multikinase inhibitor, is the only approved therapy for advanced HCC.
Jung-Chen Su +9 more
doaj +1 more source
Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression
Infectious Agents and Cancer, 2021 Background HBV promotes cell survival by upregulating the expression of the cellular inhibitor of apoptosis protein 2 (cIAP2), however whether it is involved in HBV-induced sorafenib resistance in liver cancer remains unclear.
Shouhua Zhang +9 more
doaj +1 more source
Liver Cancer, 2023 Introduction: Intratumoral administration of pexa-vec (pexastimogene devacirepvec), an oncolytic and immunotherapeutic vaccinia virus, given to patients with hepatocellular carcinoma (HCC), is associated with both local and distant tumor responses.
G. Abou-Alfa +13 more
semanticscholar +1 more source